Solid Biosciences (SLDB) Research & Development (2017 - 2026)

Solid Biosciences has disclosed Research & Development across 10 years of filings, most recently posting $46.1 million for Q1 2026.

• Research & Development for Q1 2026 came in at $46.1 million, up 49.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $155.6 million (up 43.4% YoY), and the FY2025 annual result was $140.3 million, up 45.52% from the prior year.
• Research & Development came in at $46.1 million for Q1 2026 at Solid Biosciences, up from $38.1 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $46.1 million in Q1 2026 to a low of $14.0 million in Q3 2022.
• The 5-year median for Research & Development is $23.2 million (2022), against an average of $25.8 million.
• Across the five-year window, Research & Development dropped 27.42% in 2023 and surged 99.12% in 2024, its largest moves.
• Solid Biosciences' Research & Development stood at $21.3 million in 2022, then decreased by 27.42% to $15.5 million in 2023, then soared by 99.12% to $30.8 million in 2024, then rose by 23.94% to $38.1 million in 2025, then increased by 20.99% to $46.1 million in 2026.
• The last three Research & Development figures came in at $46.1 million (Q1 2026), $38.1 million (Q4 2025), and $38.9 million (Q3 2025), per Business Quant data.